Integrase S119P mutation correlates with disease progression in HIV-1 naïve patients by Armenia, Daniele et al.
CD4 cell count and plasma HIV-RNA at baseline according to IN 
substitutions at positions 119,122 and 231  
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Patients with 119P mutation showed a higher CD4 cell 
count decline compared to those with 119G or 119Swt.  
625 HIV-1 infected individuals naïve to antiretrovirals with an available IN genotypic resistance test (GRT) have been 
analyzed.  
The prevalence of polymorphisms at HIV-1 IN positions 119, 122 and 231 was evaluated.  
Phi-coefficient correlation was calculated to evaluate potential associations between the polymorphisms at these positions. 
Potential associations between IN polymorphisms with CD4 cell count and plasma HIV-RNA at IN GRT have been evaluated 
by Mann-Whitney test.  
In a subgroup of patients deferring the treatment after diagnosis and with at least 2 HIV-RNA/CD4 cell count measurements 
before starting HAART, the time to start treatment or to reach a CD4 cell count <350 cell/mm3 was evaluated by Kaplan-Meier 
curves and Cox regression analyses. Linear mixed regression model was used to evaluate the decrease of CD4 cell count 
over time according with IN polymorphisms. The following variables were used as potential confounders in multivariable 
analyses: age, gender, subtype (B vs. non-B), CD4 cell count, plasma HIV-RNA at IN GRT and  time from HIV-diagnosis. 
To achieve productive infection, retroviruses such as HIV stably integrate their reverse transcribed 
RNA genome into a host cell chromosome. DNA integration of retroviruses is not random, instead 
each retroviral family favors DNA integration near a unique and specific subset of genomic 
features.  
• HIV integrase (IN) variants at positions 119, 122 and 231 show distinct local integration 
biases. (Demeulemeester et al., Cells Host Microbe 2014) 
• IN mutations at position S119 have been associated with HLA selection. (Brockman et al., 2012) 
• S119G and R231G are linked to disease progression in chronic HIV-1 infection in South-
African patients with subtype C. (Demeulemeester et al., Cells Host Microbe 2014) 
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Background  
Results 
Aim  
We characterized the prevalence of integrase polymorphisms at positions 119, 122 and 231 
and their association with subtype, CD4 cell-count and HIV-RNA in a large cohort HIV-1 
infected HAART-naïve patients.  
119P and 122I were the most prevalent polymorphisms at IN positions 119 and 122, 
while only 231K was rarely observed at position 231. 119P/T showed a significant higher 
prevalence in F subtype compared to  B subtype, while 122I showed a higher 
prevalence in B subtype compared to CRF02_AG or other non B subtypes. 
Male, n (%) 148 (87.6) 
Age (years), median (IQR) 35 (29 – 42) 
Viral load at IN GRT (log10 copies/mL), median (IQR) 4.60 (4.10 – 4.99) 
CD4 cell count at IN GRT (cells/mm3), median (IQR) 458 (376 – 600) 
Subtype, n (%) 
B 
CRF02_AG 
F 
C 
Other  
 
135 (79.9) 
14 (8.3) 
6 (3.6) 
2 (1.2) 
12 (7.1) 
No. of CD4 cell count measurments, median (IQR) 5 (2-7) 
Follow-up duration (months), median (IQR) 13.1 (5.5-24.1) 
Time from diagnosis (months), median (IQR) 2 (0-23) 
Among 169 patients deferring HAART, no significant difference in CD4 cell count and/or plasma HIV-RNA was found at 
baseline according to IN polymorphisms at positions 119, 122 and 231. 
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Methods 
Patients with 119P showed a shorted time to starting HAART or to 
reach a CD4 cell count <350 cell/mm3 compared to those having 
119G or 119Swt.  
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Kaplan Meyer estimates to evaluate the time of starting HAART or 
of reaching CD4 cell count <350 cell/mm3  in HAART naïve patients 
Characteristics of the 169 patients deferring HAART for 
whom disease progression was evaluated 
Mutation N 
Correlated  
mutation 
N 
Covariation  
Frequency N (%) 
Pvalue Phi 
119P 120 122I 130 51 (42.5) 6.008599e-06 0.25 
119G 56 122I 130 45 (80.3) 2.231324e-17 0.43 
119P/G and 122I were strongly associated in HIV-1 naïve patients.  
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Time from IN GRT (months)  
Adjusted mean estimate of CD4 cell count decline (cells/mm3) 
 
*Pvalue for comparison of 119P vs. 119Swt 
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P=0.034* 
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119Swt -59.1 ± 6.3 
119G -63.3 ± 14.5  
119P -103.2 ± 20.6 
Adjusted mean ± S.E.M  CD4 decline 
per 1 year longer of follow-up (cells/mm3) 
Scatter plot of CD4 cell count decline over time stratified 
according to  IN polymorphisms at position 119 
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Gender (male vs. female) 
Age (per 1 year higher) 
CD4 cell count at IN GRT 
 (per 100 cells higher) 
HIV-RNA at IN GRT  
(per 1 log higher) 
Subtype (B vs. non-B) 
Time from HIV diagnosis 
(per 1 month higher) 
119Swt 
119G 
119P 
0.1 1.0 10.0
0.168 
0.700 
<0.001 
0.002 
0.309 
0.769 
0.832 
0.001 
Variables P value .1 .  0 
Relative adjusted hazard of starting HAART 
or reaching CD4 cell count <350 cell/mm3  
Gender (male vs. Female) 
Age (per 1 year higher) 
CD4 cell count at IN GRT 
 (per 100 cells higher) 
HIV-RNA at IN GRT  
(per 1 log higher) 
Subtype (B vs. non-B) 
Time from HIV diagnosis 
(per 1 months higher) 
122Twt 
122I 
0.351 
0.726 
<0.001 
0.004 
0.420 
0.644 
  
0.730 
Variables P value 
Relative adjusted hazard of starting HAART 
or reaching a CD4 cell count <350 cell/mm3  
By Cox multivariable analysis, 119P and a higher baseline viremia were 
independent predictors of HIV-1 disease progression. Conversely, a 
higher baseline CD4 cell count was associated to a lower probability 
toward disease progression. 
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CONCLUSIONS 
 Integrase position S119, beyond the observed 
correlations with integration site targeting and host 
immune response, might define patients with 
accelerated disease progression. Further 
investigations on polymorphisms at position S119 
are necessary to understand this observation. 
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Position 119 Position 122 Position 231 
By Kaplan Meyer estimates and multivariable Cox regression, substitutions at position 122 were not associated with the probability of starting HAART 
or achieving  CD4 cell count <350 cells/mm3. 
Patients with 122I mutation showed a similar CD4 cell 
count decline compared to those showed 122Twt 
122Twt -59.1 ± 6.3 
122I -63.3 ± 14.5  
Adjusted mean ± S.E.M  CD4 decline 
per 1 year longer of follow-up (cells/mm3) 
1.62 
0.66 
2.19 
0.67 
1.50 
0.1 1.0 10 
Kaplan Meyer estimates to evaluate the time of starting HAART or 
of reaching CD4 cell count <350 cell/mm3  in HAART naïve patients 
Prevalence of polymorphisms detected at IN position 119, 122 and 231 according to subtype 
in 625 HIV-1 infected individuals naïve to antiretrovirals 
a. P value by Fisher test or Chi-Square test, where appropriate. b. A, D, K, BC, CRF01_AE, CRF02_AG, CRF03_AB, CRF06_cpx, CRF10_CD, CRF12_BF, CRF14_BG, 
CRF17_BF, CRF18_cpx, CRF18_cpx, B, CRF19_cpx, CRF31_BC, CRF37_cpx, CRF40_BF, CRF43_02G. 
a. Polymorphisms 119A/R/T, 122S/V/T and 231K were not considered because their prevalence in the overall population was <5%. 
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Even though 119P and 122I were significantly associated (see above), the impact of 119P 
on disease progression was independent from the co-presence of 122I mutation. 
Adjusted mean estimate of CD4 cell count decline (cells/mm3) 
 
*Pvalue for comparison of 122I vs. 122Twt 
Scatter plot of CD4 cell count decline over time stratified 
according to IN polymorphisms at position 122 
Mutation 
Subtype P valuea compared to B subtype  
Overall 
(N=625) 
B  
(N=445) 
CRF 
02_AG  
(N=45) 
 
F  
(N=41) 
C  
(N=23) 
G  
(N=16) 
Otherb 
(N=55) 
CRF 
02_AG 
F C G Otherb 
119Swt 396 (63.4) 285 (64) 37 (82.2) 15 (36.6) 16 (69.6) 11 (68.8) 32 (58.2) 0.014 0.001 0.59 0.7 0.394 
119P 120 (19.2) 76 (17.1) 5 (11.1) 13 (31.7) 7 (30.4) 4 (25) 15 (27.3) 0.304 0.002 0.155 0.497 0.065 
119G 56 (9.0) 51 (11.5) 0 (0.0) 2 (4.9) 0 (0.0) 1 (6.3) 2 (3.6) 0.293 0.158 1 0.101 
119T 26 (4.2) 11 (2.5) 2 (4.4) 9 (22.0) 0 (0.0) 0 (0.0) 4 (7.3) 0.339 <0.001 1 1 0.071 
119R 23 (3.7) 19 (4.3) 1 (2.2) 2 (4.9) 0 (0.0) 0 (0.0) 1 (1.8) 1 0.695 0.615 1 0.713 
119A 4 (0.6) 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 1 1 1 1 0.374 
122Twt 482 (77.1) 330 (74.2) 44 (97.8) 30 (73.2) 17 (73.9) 15 (93.8) 46 (83.6) <0.001 0.89 1 0.085 0.125 
122I 130 (20.8) 108 (24.3) 1 (2.2) 10 (24.4) 6 (26.1) 1 (6.3) 4 (7.3) <0.001 0.986 0.843 0.134 0.004 
122V 8 (1.3) 6 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 1 1 1 1 0.216 
122S 5 (0.8) 1 (0.2) 0 (0.0) 1 (2.4) 0 (0.0) 0 (0.0) 3 (3.6) 1 0.162 1 1 0.005 
231Rwt 614 (98.2) 434 (97.5) 45 (100) 41 (100) 23 (100) 16 (100) 55 (100) 1 1 1 1 1 
231K 11 (1.8) 11 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 1 1 1 1 
contact: daniele.armenia@gmail.com 
